Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22869288 | 0.97 | NT5E (0.49) | NT5EGAAALDH1A1GRIA1CACNG8 | |
| SCHEMBL22869349 | 0.95 | NT5E (0.51) | NT5EGAAALDH1A1GRIA1CACNG8 | |
| SCHEMBL24300477 | 0.85 | NT5E (0.47) | NT5EALDH1A1 | |
| SCHEMBL30409689 | 0.85 | NT5E (0.47) | NT5EALDH1A1 | |
| SCHEMBL22869290 | 0.84 | NT5E (0.49) | NT5EALDH1A1LMNA | |
| SCHEMBL22869287 | 0.84 | NT5E (0.49) | NT5EALDH1A1 | |
| SCHEMBL22869323 | 0.81 | NT5E (0.49) | NT5EGAAALDH1A1ALOX5APFEN1 | |
| SCHEMBL22869356 | 0.81 | NT5E (0.49) | NT5EGAAALDH1A1ALOX5APFEN1 | |
| SCHEMBL30477945 | 0.81 | NT5E (0.49) | NT5EGAAALDH1A1ALOX5APFEN1 | |
| SCHEMBL22869280 | 0.81 | NT5E (0.50) | NT5EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759096-B1 | CD73 INHIBITORS | LILLY CO ELI (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3759096-B1 | CD73 INHIBITORS | LILLY CO ELI (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11028074-B2 | CD73 inhibitors | ELI LILLY AND COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210002257-A1 | CD73 INHIBITORS | ELI LILLY AND COMPANY | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028074-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885GAA 1212/4885ALDH1A1 280/4885 |
| US-20210002257-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885GAA 1212/4885ALDH1A1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.